Shares and report from the company

Marinus Pharmaceuticals (NASDAQ: MRNS) today released its financial results for Q4th and full year 2021.

The company's shares opened at $9 today. However, the stock is currently trading at a loss.

Also, over the last five days, the highest value per share has been USD 11.36 and the lowest value has been USD 7.25.

The company has a market capitalisation of $329.61 billion.

The 52-week high is US$19.83 and the 52-week low for the company is US$7.16.

Report from biopharmaceutical company

As of 12/31/2021, cash and short-term investments amounted to USD 122.9 mln. BARDA of US$1.5 mln and US$6.4 mln for the 3 and 12 months ended Dec. 31, 2021.

Research and development expenses amounted to US$18 mln and US$73.5 mln for the three and twelve months ended Dec. 31, 2021.

G&A expenses were US$10.6 mln and US$37.3 mln for the 3 and 12 months (Dec. 31, 2021).

Revenues for the FY2021 from cooperation with Orion amounted to US$9 mln and one-off cooperation costs of US$1.5 mln.

Marinus Pharmaceuticals incurred net losses of US$28.3 mln and US$98.8 mln for the 3 and 12 months (Dec. 31 2021).

Marinus Pharmaceuticals (MP) was founded in 2003. Also, Scott Braunstein is CEO and Director of the company, Steven E. Pfanstiel is CFO, Joseph Hulihan is Chief Medical Officer, Christy Shafer is CMO, Martha Manning is VP, General Counsel and Secretary at Marinus Pharmaceuticals.